Close Menu

NEW YORK ─ AnchorDx said on Thursday that it has entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a four-year study to enable the early detection and diagnosis of lung cancer. Specifically, the agreement is with Johnson & Johnson (China) Investment.

Investigators will enroll and track the progress of more than 3,000 patients with pulmonary nodules identified by computed tomography scanning, according to AnchorDx, a developer of next-generation sequencing-based early cancer detection and disease monitoring tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.